• 1
    Lefebvre HP, Brown SA, Chetboul V, et al. Angiotensin-converting enzyme inhibitors in veterinary medicine. Curr Pharm Des 2007;13:13471361.
  • 2
    Dzau VJ, Bernstein K, Celermajer D, et al. Pathophysiologic and therapeutic importance of tissue ACE: A consensus report. Cardiovasc Drugs Ther 2002;16:149160.
  • 3
    Jackson EK. Renin and angiotensin. In: Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 11th ed. New York, NY: McGraw-Hill; 2006:789821.
  • 4
    Johnston CI, Fabris B, Yamada H, et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 1989;7(Suppl 5):S11S16.
  • 5
    Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: Evidence with perindopril. Expert Rev Cardiovasc Ther 2005;3:1529.
  • 6
    Davis JL, Gardner SY, Schwabenton B, Breuhaus BA. Congestive heart failure in horses: 14 cases (1984–2001). J Am Vet Med Assoc 2002;220:15121515.
  • 7
    Gehlen H, Sundermann T, Rohn K, Stadler P. Aldosterone plasma concentration in horses with heart valve insufficiencies. Res Vet Sci 2008;85:340344.
  • 8
    Reef VB. Arrhythmias. In: Marr CM, ed. Cardiology of the Horse. London; New York, NY: WB Saunders; 1999:179209.
  • 9
    Sleeper MM. Myocardial disease. In: Robinson NE, ed. Current Therapy in Equine Medicine 5. Philadelphia, PA: Saunders; 2003:620630.
  • 10
    Gardner SY, Atkins CE, Sams RA, et al. Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses. J Vet Intern Med 2004;18:231237.
  • 11
    Sleeper MM, McDonnell SM, Ely JJ, Reef VB. Chronic oral therapy with enalapril in normal ponies. J Vet Cardiol 2008;10:111115.
  • 12
    Gehlen H, Vieht JC, Stadler P. Effects of the ACE inhibitor quinapril on echocardiographic variables in horses with mitral valve insufficiency. J Vet Med A Physiol Pathol Clin Med 2003;50:460465.
  • 13
    De Luna R, Oliva G, Ambrosio R, et al. Gli ACE-inibitori nel cavallo: Valutazione del sistema renina-angiotensina-aldosterone dopo somministrazione di ramipril (Ricerche preliminari). Acta med Vet 1995;41:4150.
  • 14
    Luciani A, Civitella C, Santori D, et al. Haemodynamic effects in healthy horses treated with an ACE-inhibitor (Ramipril). Vet Res Commun 2007;31(Suppl 1):297299.
  • 15
    Toutain PL, Lefebvre HP. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors. J Vet Pharmacol Ther 2004;27:515525.
  • 16
    Costa MF, Carmona AK, Alves MF, et al. Determination of angiotensin I-converting enzyme activity in equine blood: Lack of agreement between methods of analysis. J Vet Sci 2011;12:2125.
  • 17
    Kaplan NM. Systemic hypertension: Therapy. In: Bonow RO, Mann DL, Zipes DP, Libby P, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 9th ed. Philadelphia, PA: Saunders; 2012:955974.
  • 18
    Toutain PL, Lefebvre HP, King JN. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. J Pharmacol Exp Ther 2000;292:10871093.
  • 19
    Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004;25:14541470.
  • 20
    Biollaz J, Burnier M, Turini GA, et al. Three new long-acting converting-enzyme inhibitors: Relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther 1981;29:665670.
  • 21
    Burnier M, Turini GA, Brunner HR, et al. RHC 3659: A new orally active angiotensin converting enzyme inhibitor in normal volunteers. Br J Clin Pharmacol 1981;12:893899.
  • 22
    Jacot des Combes B, Turini GA, Brunner HR, et al. CGS 13945: A new orally active angiotensin-converting enzyme inhibitor in normal volunteers. J Cardiovasc Pharmacol 1983;5:511516.
  • 23
    Hamlin RL, Nakayama T. Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal Beagles. J Vet Intern Med 1998;12:9395.
  • 24
    The COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: Results of the cooperative veterinary enalapril study group. J Vet Intern Med 1995;9:243252.
  • 25
    The BENCH Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol 1999;1:718.
  • 26
    King JN, Mauron C, Kaiser G. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. Am J Vet Res 1995;56:16201628.
  • 27
    King JN, Maurer M, Toutain PL. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats. J Vet Pharmacol Ther 2003;26:213224.
  • 28
    Lefebvre HP, Toutain PL. Angiotensin-converting enzyme inhibitors in the therapy of renal diseases. J Vet Pharmacol Ther 2004;27:265281.
  • 29
    Desmoulins PO, Burgaud S, Horspool LJ. Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat in healthy cats. J Vet Pharmacol Ther 2008;31:349358.
  • 30
    Harder S, Thurmann PA, Ungethum W. Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. Br J Clin Pharmacol 1998;45:377380.